- ISIN
- US22978P1066
- CUSIP
- 22978P106
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 2, 2018
Highlights
- Market Cap
- $129.37M
- Enterprise Value
- $117.99M
- EPS (TTM)
- -$5.19
- Total Revenue (TTM)
- $32.73M
- Gross Profit (TTM)
- $23.76M
- EBITDA (TTM)
- -$17.15M
- Year Range
- $4.97 - $41.42
- Target Price
- $4.33
- ROA (TTM)
- -63.23%
- ROE (TTM)
- -90.35%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CUE Performance Chart
Cue Biopharma, Inc. (CUE) is up 193.7% since the beginning of the year. At $27 per share, CUE is trading 35.0% below its 52-week high of $41. Investors who bought $1,000 worth of CUE shares 5 years ago would now be looking at an investment worth $68.
Loading charts...
Returns By Period
Cue Biopharma, Inc. (CUE) has returned 193.71% so far this year and 42.00% over the past 12 months.
Cue Biopharma, Inc.
- 1D
- -5.97%
- 1M
- -9.85%
- YTD
- 193.71%
- 6M
- 59.86%
- 1Y
- 42.00%
- 3Y*
- -39.79%
- 5Y*
- -41.67%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
CUE Monthly Returns History
Based on dividend-adjusted daily data since Jan 2, 2018, CUE's average daily return is +0.07%, while the average monthly return is +0.35%. At this rate, an investment would double in approximately 16.5 years.
Historically, 45% of months were positive and 55% were negative. The best month was Apr 2026 with a return of +113.7%, while the worst month was Dec 2025 at -51.5%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.
On a daily basis, CUE closed higher 46% of trading days. The best single day was May 1, 2026 with a return of +106.4%, while the worst single day was Apr 28, 2026 at -30.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 9.63% | -16.34% | -17.92% | 113.72% | 48.58% | 22.88% | 193.71% | ||||||
| 2025 | 33.03% | -15.17% | -25.93% | -17.11% | -15.51% | 6.94% | 10.01% | 3.94% | -7.88% | 6.80% | -17.93% | -51.52% | -71.98% |
| 2024 | 0.00% | -21.40% | -8.92% | 0.53% | -14.21% | -23.93% | -32.66% | -13.47% | 4.80% | 112.63% | -24.22% | -10.66% | -58.71% |
| 2023 | 20.00% | -18.13% | 27.50% | 21.29% | -7.62% | -8.75% | 4.66% | -29.06% | -15.13% | -8.70% | 19.05% | 5.60% | -7.37% |
| 2022 | -34.66% | -21.52% | -15.86% | -18.85% | -2.27% | -35.66% | 9.24% | 8.09% | -24.15% | 19.28% | 45.11% | -26.17% | -74.80% |
| 2021 | 8.23% | 0.52% | -10.36% | -0.57% | 18.22% | -18.76% | -10.56% | 15.07% | 21.52% | -16.20% | 0.41% | -7.75% | -9.59% |
Benchmark Metrics
Cue Biopharma, Inc. has an annualized alpha of 0.42%, beta of 1.27, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since January 03, 2018.
- This stock participated in 192.69% of S&P 500 Index downside but only 63.73% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 0.42%
- Beta
- 1.27
- R²
- 0.05
- Upside Capture
- 63.73%
- Downside Capture
- 192.69%
Return for Risk
Risk / Return Rank
CUE ranks 62 for risk / return — better than 62% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Cue Biopharma, Inc. (CUE) and compare them to S&P 500 Index.
| CUE | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.02 | ||
| Sortino ratioReturn per unit of downside risk | -0.84 | ||
| Omega ratioGain probability vs. loss probability | 1.27 | 1.41 | -0.14 |
| Calmar ratioReturn relative to maximum drawdown | 0.52 | 2.93 | -2.41 |
| Martin ratioReturn relative to average drawdown | 0.99 | 13.52 | -12.53 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Cue Biopharma, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cue Biopharma, Inc. was 99.42%, occurring on Apr 6, 2026. The portfolio has not yet recovered.
The current Cue Biopharma, Inc. drawdown is 97.08%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.42%Apr 2026 | 5y 10mo | — | 6y 2dJun 2020 - now |
Rate-hike selloffLate 2018 | -74.78%Dec 2018 | 9mo 22d | 1y | 1y 9moMar 2018 - Dec 2019 |
COVID crash2020 | -55.77%Mar 2020 | 12d | 1mo 5d | 1mo 17dMar 2020 - Apr 2020 |
2020 bear market2020 | -21.64%Jan 2020 | 7d | 1mo 5d | 1mo 12dDec 2019 - Feb 2020 |
COVID crash2020 | -15.71%Feb 2020 | 7d | 5d | 12dFeb 2020 - Mar 2020 |
Drawdown Indicators
| CUE | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.42% | -56.78% | -42.64% |
Max Drawdown (1Y)Largest decline over 1 year | -80.89% | -9.10% | -71.79% |
Max Drawdown (3Y)Largest decline over 3 years | -96.23% | -18.90% | -77.33% |
Max Drawdown (5Y)Largest decline over 5 years | -99.01% | -25.43% | -73.58% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -97.08% | -0.74% | -96.34% |
Average DrawdownAverage peak-to-trough decline | -69.53% | -10.72% | -58.81% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 42.63% | 1.97% | +40.66% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Cue Biopharma, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Cue Biopharma, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CUE relative to other companies in the Biotechnology industry. Currently, CUE has a P/S ratio of 3.1. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CUE in comparison with other companies in the Biotechnology industry. Currently, CUE has a P/B value of 6.0. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CUE
Add Cue Biopharma, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CUE